Navigation Links
Nephros Signs Development Agreement with STERIS
Date:3/23/2010

RIVER EDGE, N.J., March 23 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today reported that is has entered into a development agreement with STERIS Corporation ( STE).

Under the terms of the agreement, Nephros and STERIS will jointly develop filtration-based products for medical device applications.  Nephros received an initial payment upon entering into the agreement and is eligible to receive additional payments upon successful completion of product development milestones.

"Nephros is investigating a range of commercial, industrial and retail opportunities for its DSU technology," said Ernest Elgin, President and CEO of Nephros.  "We are pleased to be working with STERIS to leverage our expertise in additional applications.  STERIS is a leader in the field of medical device sterilization, and we look forward to developing new products together to enhance patient safety."

In 2009, Nephros received 510(k) marketing approval from the FDA for the Dual Stage Ultrafilter (DSU) to be used to filter biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures.  In August 2009, Nephros reported that it was awarded a new research contract from the U.S. Office of Naval Research ("ONR") for development of a portable dual-stage purifying filter.

About STERIS

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company has approximately 5,000 dedicated employees around the world working together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government Customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.

About Nephros, Inc.

Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.  The Nephros DSU is the basis for the Nephros line of water filtration products. The patented dual stage ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins.

For more information about Nephros, please visit our website at http://www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros' control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to obtain additional funding when needed or on favorable terms; (ii) to continue as a going concern; (iii) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (iv) to have its technologies and products accepted in current or future target markets; (v) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; or (vi) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros' filings with the SEC, including Nephros' Annual Report on Form 10-K for the fiscal year ended December 31, 2008. Investors and security holders are encouraged to read these documents on the SEC's website at http://www.sec.gov/. Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

SOURCE Nephros, Inc.

Back to top

RELATED LINKS
http://www.nephros.com

'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
4. Water Street Healthcare Partners Signs Definitive Agreement to Sell Sierra Scientific Instruments to Given Imaging
5. MedeFile Signs Distribution Pact with Roadside Assist Giant NSD
6. San Diego Based CRO Signs Agreement With UK Based Spinal Device Manufacturer
7. Watson Signs Agreement to Divest Equity Interest in ScinoPharm
8. Pro Medicus/Visage Imaging Signs Deal with Sydney-based Southern Radiology
9. Amedica(R) Signs Joint Venture Agreement With Orthopaedic Synergy(R)
10. International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain
11. Delcath Signs First Partner Agreement in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 ARANZ Medical ... the healthcare sector, has been named the Coretex Hi-Tech Emerging ... 2016. Dr Bruce Davey , CEO of ... team.  It,s really good to be recognised for the work ... products are used in 35 countries around the world from ...
(Date:5/24/2016)... -- The innovator of COMBO ... s first dual therapy stent, introduces catheters for lower ... a global company specializing in the provision of life-changing ... to treat peripheral artery disease. The JADE™ and Scoreflex™ ... lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... May 24, 2016 Dutch surgeons have launched ... around the world and treat patients on a global scale. Medical ... , Asia and the US have already ... messaging and networking in a totally secure environment. Education  ... war zone working together with a surgeon at Harvard to treat ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... OncLive® , a leading digital provider ... University of Virginia (UVA) Cancer Center to its quickly expanding Strategic ... will publicize and promote public awareness of UVA Cancer Center’s latest advances in ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & Associates’ ... 20 years of experience in leading technology and human resources operations for health ... teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , Innovative ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... nominations to serve on its Accreditation and Standards Committees and support the ... activities incorporate key process and outcome measures, with the ultimate mission of ...
(Date:5/26/2016)... , ... May 26, 2016 , ... According to the ... an industry filled with chemical-laden beauty products, one company is going against the norm ... you: Mad Hippie. The rising star in the green space is proud to announce ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Bunion ... for family members, friends... and yourself and save. For a limited time only (offer ... already offered when buying more than one, by using the promo code "Memorial" at ...
Breaking Medicine News(10 mins):